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Colorectal cancer (CRC) is one of the most frequent cancers and is a leading cause of cancer death worldwide. Treatments used
for CRC may include some combination of surgery, radiation therapy, chemotherapy, and targeted therapy. The current standard
drugs used in chemotherapy are 5-fluorouracil and leucovorin in combination with irinotecan and/or oxaliplatin. Most recently,
biologic agents have been proven to have therapeutic benefits inmetastaticCRCalone or in associationwith standard chemotherapy.
However, patients present different treatment responses, in terms of efficacy and toxicity; therefore, it is important to identify
biological markers that can predict the response to therapy and help select patients that would benefit from specific regimens. In
this paper, authors review CRC genetic markers that could be useful in predicting the sensitivity/resistance to chemotherapy.
1. Introduction
Colorectal cancer (CRC) is one of the most frequent cancers
worldwide, being the third most frequent in men (10% of the
total) and the second in women (9.2% of the total). Moreover,
themortality rate caused by CRC is the fourth highest inmen
(8% of the total) and the third in women (9% of the total) [1].
Several molecular mechanisms have been identified in
CRC carcinogenesis, such as oncogenes activation, tumor
suppressor genes inactivation [2], mutations in mismatch
repair (MMR) genes, microsatellite instability (MSI) [3], and
epigenetic alterations [4]. The accumulation of such alter-
ations ultimately leads to neoplastic transformation.
The standard drugs for CRC chemotherapy are 5-flu-
orouracil (5-FU) and leucovorin (LV) in combination with
irinotecan and/or oxaliplatin [5]. Current guidelines suggest
the use of FOLFOX (5-FU/LV with oxaliplatin) or CapeOx
(capecitabine and oxaliplatin) in stage III CRC, after surgical
resection [6].TheMOSAIC (Multicenter International Study
of Oxaliplatin/5-FU/LV in the Adjuvant Treatment of Colon
Cancer) trial showed significant improvements in disease-
free survival (DFS) and overall survival (OS) for FOLFOX
compared with FL (5-year DFS: 73.3% versus 67.4%, resp.,
(𝑝 = 0.003) and 6-year OS 78.5% versus 76.0% (𝑝 = 0.046))
in stage III CRC but not in stage II [7]. The use of CapeOx
regimen in the treatment of patients with stage III CRC
showed an increase in 7-year OS when compared with those
treated with 5-FU/LV (73% versus 67%; hazard ratio [HR]:
0.83; 95% confidence interval [CI]: 0.70–0.99; 𝑝 = 0.04) [8].
In 2009, the PETACC-3 study investigated the efficacy of
FOLFIRI (FU/LV with irinotecan) versus the 5-FU/LV reg-
imen in patients with stage III CRC, with no significant dif-
ferences in 5-year OS (73.6% versus 71.3% [𝑝 = NS]) and DFS
(56.7% versus 54.3% [𝑝=NS]).Therefore, regimens including
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The use of adjuvant chemotherapy has been proven to
increase OS in patients with stage III CRC but in stage II
CRC this data remain controversial. That may suggest that
the use of adjuvant chemotherapy has a greater advantage in
people with higher risk [10].Therefore, National Comprehen-
sive Cancer Network (NCCN) guidelines recommend that
treatment with 5-FU/LV, capecitabine, FOLFOX, CapeOx,
or bolus 5-FU/LV/oxaliplatin (FLOX) should be considered
in patients with stage II CRC and high risk of recurrence,
defined as those with T4 tumors (stage IIB/IIC); poorly dif-
ferentiated histology (exclusive of those cancers that areMSI-
high [MSI-H]); lymphovascular invasion; bowel obstruction;
lesions with localized perforation or close, indeterminate, or
positive margins; or inadequately sampled nodes (<12 lymph
nodes). In this setting, analyzing MSI plays a crucial role in
the decision of whether to use adjuvant therapy in patients
with stage II CRC [6]. This issue will be addressed later in
this paper.
Metastatic CRC (mCRC) has been shown to benefit
from neoadjuvant and adjuvant chemotherapy. A 2012 meta-
analysis combining data from 3 studies and 642 patients
showed an increase inDFS (pooledHR, 0.71; CI, 0.582–0.878;
𝑝 = 0.001) and progression-free survival (PFS) (pooled HR,
0.75; CI, 0.620–0.910; 𝑝 = 0.003) in CRC patients with liver
metastasis treated with surgery plus chemotherapy, when
compared to those treated with surgery alone. However, no
increase on OS was observed (pooled HR, 0.743; CI, 0.527–
1.045; 𝑝 = 0.088) [11]. More recently, another meta-analysis
showed similar results regarding perioperative chemotherapy
in patients with resectable colorectal hepatic metastasis when
compared to surgery alone.The data from 1896 patients from
10 studies showed a significant benefit in DFS in those who
received perioperative therapy (HR, 0.81; 95% CI, 0.72–0.91;
𝑝 = 0.0007) but no significant statistical difference in OS
(HR, 0.88; 95% CI, 0.77–1.01; 𝑝 = 0.07) [12].
According to current NCCN guidelines, one of the fol-
lowing regimens should be used in systemic chemotherapy
of mCRC: FOLFOX, FOLFIRI, CapeOx, infusional 5-FU/LV
or capecitabine, or FOLFOXIRI (FU/LV with oxaliplatin and
irinotecan) [6]. Over the years, several studies were per-
formed in order to evaluate the efficacy of one regimen over
the others. In 2005, theGOIM (GruppoOncologico dell’Italia
Meridionale) trial compared the efficacy of FOLFIRI versus
FOLFOX regimens in 360 patients. The results showed no
differences in OS (15 versus 14 months [𝑝 = NS]), response
rate (RR) (31% versus 34% [𝑝 =NS]), and time to progression
(TTP) (7 versus 7 months [𝑝 = NS]) [13]. Two other clinical
trials tried to compare the efficacy and toxicity of FOLFIRI
versus FOLFOXIRI regimens. Souglakos et al. found no
differences inOS (19.5 versus 21.5months [𝑝 =NS]), RR (34%
versus 43% [𝑝 = NS]), and TTP (6.9 versus 8.4 months [𝑝
= NS]) [14]. On the other hand, Falcone et al. showed an
improvement in RR (60% versus 34% [𝑝 < 0.0001]) and PFS
(9.8 versus 6.9 months [𝑝 = 0.0006]) for the FOLFOXIRI
group however at cost of increased toxicity (𝑝 < 0.001) [15].
A randomized trial compared the efficacy of CapeOx versus
FOLFOX, with results showing no significant differences
in PFS (8.0 versus 8.5 months, resp.) (HR, 1.04; 97.5% CI,
0.93–1.16) and OS (19.6 versus 19.8 months, resp.) (HR, 0.99;
97.5% CI, 0.88–1.12) [16].
Most recently, biologic agents such as cetuximab/panitu-
mumab (monoclonal antibodies directed against the EGFR
[epidermal growth factor receptor]) and bevacizumab (a
humanized monoclonal antibody that targets VEGF [vas-
cular endothelial growth factor]) have been proven to have
therapeutic benefits in mCRC alone or in association with
standard chemotherapy. In the CRYSTAL trial, Van Cutsem
et al. investigated the efficacy of cetuximab plus FOLFIRI
as first-line treatment for mCRC versus FOLFIRI alone in
a total of 599 patients. There was an increase in PFS in the
cetuximab-FOLFIRI group (HR, 0.85; 95%CI, 0.72–0.99;𝑝 =
0.048), but there was no difference in OS (HR, 0.93; 95% CI,
0.81–1.07;𝑝 = 0.31) [17]. Another study involving 813 patients
with previously untreated mCRC compared the efficacy of
bevacizumab along with irinotecan, bolus fluorouracil, and
LV (IFL) versus IFL alone. Results showed an improvement
in median survival (HR, 0.66 [𝑝 < 0.001]), PFS (HR, 0.54;
𝑝 < 0.001), overall response rate (44.8% versus 34.8% [𝑝 =
0.004]), andmedian duration of relapse (HR, 0.62;𝑝 = 0.001)
in the group treatedwith bevacizumab [18].Therefore, the use
of these targeted agents can be considered as initial therapy
for mCRC, together with one of the regimens mentioned
above [6].
Despite all the evidence and current recommendations,
patients present different responses to treatment, regarding
efficacy and toxicity. Therefore, it is important to identify
biological markers that can predict the response to therapy
and help select patients that would benefit from specific
regimens [19].
In this paper, authors review CRC genetic markers that
could be useful in predicting the sensitivity/resistance to
chemotherapy.
2. 5-Fluorouracil
5-FU is the basis of CRC chemotherapy regimens. Its anti-
tumor effect relies on the inhibition of thymidylate synthase
(TS), the rate-limiting enzyme in the formation of thymidy-
late (TMP), which is essential for DNA synthesis. 5-FU enters
cells and is converted to fluorodeoxyuridinemonophosphate,
which is the substrate to TS [20].
Studies have shown that tumors that express high levels
of TS are associated with resistance to 5-FU [21, 22]. A
study correlated the TS protein and gene expression with
response to 5-FU based therapy in patients with CRC and
gastric cancer. Patients with responsive disease had a mean
TS protein level of 0.17 ± 0.03 arbitrary units (range, 0.05
to 0.38), whereas in patients whose tumors did not respond,
the mean TS protein level was significantly higher, 0.60 ±
0.09 (range, 0.06 to 1.01; 𝑝 < 0.01). Similarly, in patients
with responsive disease, the mean TS :𝛽-actin gene ratio was
1.36 ± 0.3 (range, 0.5–3.3). On the other hand, biopsies from
patients with unresponsive disease had a mean TS :𝛽-actin
gene ratio of 15.4 ± 2.6 (range, 2.7–35.9; 𝑝 < 0.01) [21]. A
meta-analysis involving twenty studies tried to estimate the
prognostic significance of TS expression in both advanced
and localized CRC. The combined HR estimate for OS was
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1.74 (95% CI, 1.34 to 2.26) and 1.35 (95% CI, 1.07 to 1.80) in
the advanced and adjuvant settings, respectively. However,
the authors assume possible existence of heterogeneity and
publication bias [22].
The variability in TS expression seems to be related to
polymorphisms in the TS promoter enhancer region (TSER),
which determines TS expression. The two most common
polymorphisms are the 3R and 2R variants. One study
showed that mCRC with the 3R homozygous polymorphism
(3R/3R) had higher levels of TS when compared with the
2R homozygous variant (2R/2R). In this trial, 50 patients
withmCRCwere treated with 5-FU. Individuals homozygous
for the 3R variant had 3.6 times higher TS mRNA levels
compared to those homozygous for the 2R variant in tumor
tissue (𝑝 = 0.004). The authors then evaluated whether the
TS polymorphism could predict the clinical outcome. The
RR of individuals carrying the 2R/2R genotype was 50%
against 9% of the 3R/3R patients (𝑝 = 0.041). Heterozygous
individuals showed RR of 15%. Moreover, patients displaying
the 3Rhomozygous polymorphismhad less severe side effects
to 5-FU (𝑝 = 0.008) [23].
However, there are 3R/3R variants that express low levels
of TS. The cause appears to be a single nucleotide polymor-
phism (SNP) in the 3R allele, inwhich a guanine is substituted
by a cytosine, resulting in low TS expression [24]. Tumors
expressing this polymorphism could therefore benefit from
therapy with 5-FU.
Another aspect that should be taken into account is the
loss of heterozygosity (LOH) that has been observed in the
TS locus of CRC. When LOH is present, in 2R/3R variant,
it could originate either a 2R/loss or a 3R/loss tumor. This
would ultimately affect its sensitivity to fluoropyrimidine-
based regimens [25].
Thymidine phosphorylase (TP) is another enzyme in-
volved in nucleotide metabolism. Concerning fluoropyrim-
idine therapy, TP is responsible for the conversion of 5󸀠-
deoxy-5-fluorouridine (5󸀠-FUR) into 5-FU. TP has been
proven to have a dual role in CRC: it is necessary for 5-FU
prodrug activation and it has a role in promoting angiogen-
esis. Tsujitani et al. investigated the prognostic significance
of microvessel density and the relationship between the
expression of VEGF, TP, and angiogenesis in patients with
gastric carcinoma.Their results revealed that tumors positive
for VEGF and TP had high microvessel density, while VEGF
and TP negative tumors showed lowmicrovessel density.This
evidence strongly suggests an association of TP with tumor
neovascularization [26].
Even though high tumor TP expression leads to increased
angiogenesis and therefore a poor prognosis (which is linked
to increased infiltration, growth, and metastization) [27], it
has been documented that it also increases sensitivity to 5-
FU and thus its effectiveness in CRC treatment [28].
Tumor response to 5-FU therapy also depends on its
bioavailability to ultimately inhibit DNA synthesis. DPD is
the rate-limiting enzyme in 5-FU catabolism [29]; hence,
high levels of DPD are linked with reduced fluoropyrimidine
sensitivity, probably due to its decreased cytotoxic effect.
Kornmann et al. showed that, among CRC patients treated
with 5-FU, those who displayed low levels of DPD survived
longer than those with high DPD tumors. They then con-
cluded thatDPDmay have a prognostic value inCRCpatients
and those who would benefit the most from 5-FU based
chemotherapy would be the ones who express the lowest
levels of DPD [30]. Similarly, another study revealed that
tumors from CRC patients who responded to therapy with
5-FU presented low levels of DPD [31].
Kornmann et al. tried to determine the prognostic value
of TS and dihydropyrimidine dehydrogenase (DPD) in CRC
patients receiving 5-FU. Resulting data showed that, among
those treated with this drug, the ones who displayed higher
levels of TS presented a better prognosis. Additionally, in each
TS group, patients with low DPD survived longer than the
ones with high DPD levels. Furthermore, the authors con-
sider that the combination of TP and DPD is an independent
prognostic factor for survival (𝑝 = 0.030) [30].
Nevertheless, individuals with DPD deficiency experi-
ence severe toxicity to 5-FU [32, 33]. Van Kuilenburg et al.
performed a study, in which they evaluated the importance
of DPD deficiency in 5-FU toxicity. They conducted a DPD
activity, DPD gene, and clinical presentation analysis after 5-
FU administration. Results demonstrated that 55%of patients
with a decreased DPD activity suffered from grade IV
neutropenia compared with 13% of patients with a normal
DPD activity (𝑝 = 0.01). Moreover, toxicity was observed
twice as fast in patients with low DPD activity as compared
with patients with a normal DPD activity (10.0 ± 7.6 versus
19.1 ± 15.3 days; 𝑝 < 0.05) [33].
3. Irinotecan
Irinotecan is an inhibitor of DNA topoisomerase I used in
CRC treatment, usually in combination with 5-FU, as pre-
viously mentioned. It is a prodrug which is then converted
to SN-38, the active metabolite that exerts both the anti-
tumor and toxic effects [34]. SN-38 is then conjugated by
UDP-glucuronosyltransferase 1A1 (UGT1A1) to SN-38G, an
inactive metabolite [35]. UGT1A1 deficiency, caused by some
polymorphisms, results in SN-38 accumulation, causing iri-
notecan-related toxicity, which includes diarrhea, dehydra-
tion and neutropenia.
TheUGT1A1 enzyme is also involved in converting biliru-
bin into more soluble forms. Therefore, UGT1A1 deficiency
can also lead to accumulation of unconjugated bilirubin, as
seen in Crigler-Najjar and Gilbert syndromes [36, 37].
TheUGT1A1∗28 polymorphism has been linked to severe
side effects, namely, neutropenia and diarrhea. In this variant,
the UGT1A1 expression is markedly decreased which leads to
prolonged exposure to SN-38 [38]. In a 2014 meta-analysis,
sixteen studies were included in order to investigate the asso-
ciation of UGT1A1 polymorphisms and irinotecan-induced
diarrhea and neutropenia. UGT1A1∗28/∗28 genotype was
associated with more than fourfold (OR, 4.79; 95% CI, 3.28–
7.01; 𝑝 < 0.00001) and threefold (OR, 3.44; 95% CI, 2.45–
4.82; 𝑝 < 0.00001) increases in the risk of neutropenia when
compared with wild type and with at least one UGT1A1∗1
allele, respectively. Moreover, UGT1A1∗28/∗28 genotype was
associated with a twofold risk of diarrhea (OR, 1.84; 95% CI,
1.24–2.72; 𝑝 = 0.002). Additionally, the incidence of diarrhea
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was higher when irinotecan was given at higher doses (OR,
2.37; 95% CI, 1.39–4.04; 𝑝 = 0.002) [37]. In 2005, the Food
andDrug Administration (FDA) recommended that individ-
uals homozygous for UGT1A1∗28 polymorphism would start
the treatment with irinotecan with lower doses.
While UGT1A1∗28 is a common variant in both Cau-
casians and Asians, UGT1A1∗6 is another polymorphism
that is only found in Asians and has similar toxic effects of
those of the UGT1A1∗28 variant. A systematic review ana-
lyzed the association between UGT1A1∗6 polymorphisms
and irinotecan-induced neutropenia and diarrhea in Asian
patients. Patients with UGT1A1∗6/∗6 genotype displayed an
increased risk for severe neutropenia (OR, 4.44; 95% CI;
2.42–8.14; 𝑝 < 0.001). Individuals carrying the heterozygous
variant also showed a higher risk for neutropenia, although
not as high as the homozygous variant (OR, 1.98; 95% CI;
1.45–2.71; 𝑝 < 0.001). UGT1A1∗6 homozygous patients were
at higher risk for severe diarrhea (OR, 3.51; 95% CI; 1.41–
8.73; 𝑝 = 0.007), while heterozygous patients had no signif-
icant risk. Therefore, UGT1A1∗6 polymorphisms are poten-
tial biomarkers predicting irinotecan-induced severe toxicity
in Asian patients. In this context, since 2008, Japan has
been recommending the screening of patients for these two
polymorphisms [39].
Even though genotyping for the UGT1A1 polymorphisms
could be important in order to prevent severe adverse
effects such as neutropenia, it does not predict response to
chemotherapy.
4. Oxaliplatin
Oxaliplatin is a platinumanalog chemotherapeutic agentwith
a 1,2-diaminocyclohexane (DACH) carrier ligand. It forms
adducts on DNA strands, leading to DNA damage [26]. The
nucleotide excision repair (NER) pathway is responsible for
the removal of these adducts, reducing sensitivity to oxali-
platin.The twomajor genes involved in the NER pathway are
excision repair cross-complementation group 1 (ERCC1) and
xeroderma pigmentosa [27]. ERCC1 overexpression has been
associated with resistance to oxaliplatin, probably because
it induces repair of DNA strands. In 2001, Shirota et al.
revealed that intratumoral ERCC1 mRNA expression levels
are an independent predictive marker of survival for 5-FU
and oxaliplatin combination chemotherapy in 5-FU-resistant
mCRC. Patients with a low ERCC1 expression level had a
greater median survival time than those with high levels of
ERCC1 mRNA (10.2 versus 1.9 months, resp.; 𝑝 < 0.001)
[40]. Amore recent study involving 180 stage III CRCpatients
treated with FOLFOX-4 showed that ERCC1 overexpression
is an important predictor of early failure (𝑝 = 0.005), DFS
(𝑝 < 0.001), and OS (𝑝 < 0.001) [41]. However, conflicting
data have been observed about the association of ERCC1 and
clinical outcome in CRC patients treated with oxaliplatin.
Li et al. conducted a trial to investigate the relationship
between ERCC1 and DFS in Chinese CRC patients receiving
oxaliplatin plus 5-FU. Results failed to show ERCC1 mRNA
levels as a predictive factor for DFS (𝑝 = 0.638) [42].
Similar conclusions were achieved by Kim et al. in stage
II and stage III CRC patients who underwent a curative
resection followed by FOLFOX-4 adjuvant chemotherapy.
ERCC1 expression was not significantly correlated with the
5-year DFS (𝑝 = 0.396) and therefore cannot be used as a
prognostic factor [43].
Based on the inconsistent results concerning ERCC1 role
in predicting patients’ response to therapy, a meta-analysis
was performed in order to elucidate the prognostic role of
ERCC1 expression in patients with CRC. A total of 11 studies
were analyzed. Results revealed that patients with higher
ERCC1 expression showed a poorer OS (HR, 2.325; 95% CI;
1.720–3.143; 𝑝 < 0.001), PFS (HR, 1.917; 95% CI; 1.366–2.691;
𝑝 < 0.001), and response to chemotherapy (HR, 0.491; 95%
CI; 0.243–0.990; 𝑝 = 0.047), when compared to those with
low ERCC1 expression. Therefore, the authors conclude that
ERCC1 can indeed be a prognostic factor for OS, PFS, and
response to chemotherapy [44]. However, further studies
need to be addressed in order to better understand the true
prognostic value of this biomarker.
Some studies showed that ERCC1-118 polymorphism
influences response to oxaliplatin-based therapy. Further-
more, the allele ERCC1-118T induces higher levels of ERCC1
mRNA, which may explain why it is associated with shorter
PFS in patients with mCRC treated with FOLFOX-4 regimen
[45, 46]. This was also documented for XPD-751 polymor-
phism holding the C allele. Moreover, the combination of
ERCC1-118 T/T genotype with either XPD-751 A/C or XPD-
751 C/C resulted in an even shorter PFS (HR, 2.84; 95% CI,
1.47–0.45; 𝑝 = 0.002), compared to the case when only one
of these genotypes was present [46]. More recently, another
study showed that the XPG Arg1104His polymorphism vari-
ants were associated with a longer DFS in patients receiving
oxaliplatin-based chemotherapy [47]. Based on current data,
ERCC1 screening is not recommended to select patients for
oxaliplatin-based regimens.
5. Antibodies Targeting EGFR
The activation of EGFR induces cell proliferation by activat-
ing two main downstream signaling pathways, the Ras/Raf/
mitogen-activated protein kinase (MAPK) (mainly responsi-
ble for cell proliferation) and the PI3KPTEN-AKT (mainly
responsible for cell survivor) pathways.
Themonoclonal antibodies cetuximab and panitumumab
are directed against EGFR, therefore inhibiting cell prolif-
eration and tumor growth, by binding to the extracellular
domain of EGFR and blocking ligand-induced receptor phos-
phorylation and further signaling [48]. Response to EGFR-
targeted therapy varies greatly between individuals, and it is
not correlated with EGFR levels. A clinical trial conducted
by Cunningham et al. showed that the degree of EGFR
expression, either as the percentage of EGFR-positive tumor
cells or as the maximal staining intensity per cell, had no
relation to the clinical response rate (𝑝 = 0.67 and 𝑝 = 0.84,
resp.) [49]. Another study, designed to access the antitumor
activity and toxicity of cetuximab in patients whose tumors
express the EGFR, displayed similar results. Moreover, 88%
of the patients presented skin reactions, such as acne-like rash
and paronychia cracking, as well as allergic reactions, which
in two cases led to therapy cessation.The authors also verified
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a statistical correlation between the presence and severity of
the acne-like rash and survival (𝑝 = 0.02) [50]. Given the
possible adverse effects of cetuximab, it is important to be able
to select the patients that would benefit from therapy with
this agent. Once scientific evidence showed no correlation
between EGFR expression and clinical response, it was
hypothesized that gene mutations in downstream proteins
could be responsible for cetuximab/panitumumab resistance.
KRAS has been widely studied in the context of cetux-
imab/panitumumab response in mCRC. Several studies
showed that KRAS mutations are highly predictive of cetux-
imab resistance in patients with mCRC. The most common
KRASmutations occur at exon-2 (codons 12 and 13), although
those have also been found in exon-3 and exon-4 [51–53].
As previously mentioned, the CRYSTAL trial was con-
ducted to investigate the efficacy of cetuximab plus irinote-
can, 5-FU, and LV (FOLFIRI) as first-line treatment for
mCRC [17]. The results showed improvement in PFS but not
inOS in patients treatedwith cetuximab.However, in a subset
analysis of patients with wild-type KRAS, the addition of
cetuximab to FOLFIRI resulted in significant improvements
in OS (median, 23.5 versus 20.0 months; HR = 0.796; 𝑝 =
0.0093), PFS (median, 9.9 versus 8.4 months; HR = 0.696;
𝑝 = 0.0012), and RR (57.3% versus 39.7%; OR = 2.069; 𝑝 =
0.001) compared with FOLFIRI alone. No significant differ-
ence in efficacy was evident in patients with mutant KRAS
(codons 12 and 13, exon-2) [17, 54]. Most recently, a revision
of the CRYSTAL study showed that not only the mutations in
codons 12 or 13 were linked to worst response to cetuximab
plus FOLFIRI, but also the same was true to mutations in
exon-3 and exon-4. DNA samples from CRYSTAL patients
that presented a KRAS wild-type status for mutations in
codons 12 and 13 were reanalyzed for mutations in four
additional KRAS codons (exon-3 and exon-4) and six NRAS
codons (exon-2, exon-3, and exon-4). Results showed no
differences in OS and PFS between patients treated with cet-
uximab plus FOLFIRI and FOLFIRI alone [55].
Three important studieswere conducted in order to assess
the efficacy of FOLFOX plus cetuximab versus FOLFOX
alone. In the OPUS (Oxaliplatin and Cetuximab in First-
Line Treatment ofMetastatic Colorectal Cancer) study, Boke-
meyer et al. showed that the addition of cetuximab to
FOLFOX-4, as first-line therapy in patients with mCRC,
resulted in better response to chemotherapy (OR = 2.551;
𝑝 = 0.0027) and PFS (HR = 0.567; 𝑝 = 0.0064) in wild-type
KRAS individuals when compared with those treated with
FOLFOX-4 alone. Those who held the KRAS exon-2 muta-
tions showed no benefit from cetuximab, as they presented
with worse response to treatment and shorter PFS [56].
Another study called COIN also compared the efficacy of
FOLFOX plus cetuximab versus FOLFOX alone in 1630
patients. In this trial, Maughan et al. showed that FOLFOX
with cetuximab increased RR compared with FOLFOX alone
(64% versus 57%, resp.; 𝑝 = 0.049). However, no evidence of
improved PFS (8.6 versus 8.6 months, resp.; HR = 0.96, 95%
CI = 0.82–1.12, and 𝑝 = 0.60) or OS (17.0 versus 17.9 months;
HR = 1.04, 95% CI = 0.87–1.23, and 𝑝 = 0.67) was seen
among patients with wild-type KRAS. Furthermore, skin and
gastrointestinal toxic effects were more frequent in the group
treated with FOLFOX plus cetuximab compared to control
group (14 versus 114 and 67 versus 97, resp.) in patients with
KRAS wild-type tumors [57].
A multicenter phase III trial named NORDIC-VII inves-
tigated the efficacy of cetuximab plus a bolus of fluo-
rouracil/folinic acid and oxaliplatin (Nordic FLOX), admin-
istered continuously or intermittently, in 571 patients with
previously untreated mCRC. Therefore, the patients were
randomly divided into three groups, one receiving standard
Nord FLOX (armA), another receiving FLOXplus cetuximab
(arm B), and a third group treated with cetuximab plus
intermittent FLOX (arm C). OS, PFS, and RR were similar in
the 3 treatment arms (OS = 20.4, 19.7, and 20.3 months, resp.
[𝑝 = NS]; PFS = 7.9, 8.3, and 7.3 months [𝑝 = NS]; and RR:
41%, 49%, and 47% [𝑝 =NS]). In KRASwild-type tumors, the
addition of cetuximab did not bring about additional benefits.
In KRAS mutant tumors, improvement in PFS was reported
in arm B for patients treated with cetuximab when compared
with those receiving FLOX alone. However, this difference
was not statistically significant (7.8 versus 9.2 months; HR =
0.71; 𝑝 = 0.07) [58]. Based on these studies, the screening of
patients with mCRC to exon-2 KRAS mutations is currently
recommended. However, 65% of the wild-type patients for
the exon-2 mutation are resistant to cetuximab, which brings
up the importance of using new biomarkers such as exon-3
and exon-4 mutations [59].
KRAS has also been studied in the setting of panitumum-
ab use in patients with chemotherapy-refractory mCRC.
Also in this case, only the KRAS wild-type patients showed
sensitivity to monotherapy with panitumumab. Amado et
al. conducted a phase III trial, in which they compared
the efficacy of panitumumab as monotherapy for mCRC to
best supportive care (BSC). Additionally, the authors of this
study tried to evaluate whether the efficacy of panitumumab
was related to KRAS status. Results showed that, in those
treated with panitumumab, PFS was significantly increased
(HR, 0.45; 95% CI, 0.34–0.59; 𝑝 < 0.0001) in the wild-type
KRAS group compared to KRAS mutant group (HR, 0.99;
95% CI, 0.73–1.36). In patients with KRAS wild-type mCRC
tumors, treatment with panitumumab resulted in higher PFS
(HR, 0.45; 95% CI, 0.34–0.59; median PFS of 12.3 weeks
for panitumumab versus 7.3 weeks for BSC). Contrarily,
in the KRAS mutant group, no improvement in PFS was
observedwith therapywith panitumumab (HR, 0.99; 95%CI,
0.73–1.36; median PFS of 7.4 weeks for panitumumab versus
7.3 weeks for BSC) [60]. The phase III PRIME trial compared
the efficacy and safety of FOLFOX-4 versus FOLFOX-4 plus
panitumumab in mCRC patients with no previous chem-
otherapy treatment. Data from 1183 patients was collected.
Among patients with KRAS wild-type tumors, results dis-
played a significant improvement in PFS in the group treated
with FOLFOX-4 and panitumumab, when compared to the
FOLFOX-4 group (9.6 versus 8.0 months, resp.; HR, 0.80;
95% CI, 0.66–0.97; 𝑝 = 0.02). No differences in OS were
observed (23.9 versus 19.7 months, resp.; HR, 0.83; 95% CI,
0.67–1.02; 𝑝 = 0.072). On the other hand, in the mutant
KRAS stratum, there was a significant decrease in PFS in
the FOLFOX-4 plus panitumumab group (HR, 1.29; 95% CI,
1.04–1.62; 𝑝 = 0.02). Median OS was 15.5 months versus 19.3
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months, respectively (HR, 1.24; 95% CI, 0.98–1.57; 𝑝 = 0.068)
[61]. Therefore, patients who are candidates to therapy with
panitumumab are indicated for screening for KRAS codons
12 and 13 mutations [60].
BRAF is an oncogene that encodes a downstream effector
of KRAS in the MAPK pathway. Mutations in this gene may
explain some of the cases in which KRAS wild-type patients
do not respond to cetuximab/panitumumab therapy. The
most commonmutation found on BRAF is V600E, which has
been shown to induce resistance to EGFR-targeted therapy.
In a retrospective study, Di Nicolantonio et al. analyzed
tumor responses, PFS, OS, and themutational status of KRAS
and BRAF in 113 tumors from cetuximab- or panitumumab-
treated mCRC patients [62]. Data showed decreased PFS
(𝑝 = 0.011) and OS (𝑝 < 0.0001) in patients with BRAF
mutations. Furthermore, none of the patients that displayed
the BRAF mutation responded to therapy and none of the
responders carried this mutation (𝑝 = 0.029). This evidence
suggested that the introduction of the V600E allele impaired
the therapeutic effect of cetuximab/panitumumab.Therefore,
the authors hypothesized that a BRAF inhibitor could restore
the sensitivity to these drugs. Sorafenib, a clinically approved
small-molecule kinase inhibitor, was then used to phar-
macologically target BRAF. Results showed that sorafenib
restored sensitivity to panitumumab or cetuximab of CRC
cells carrying the V600E allele [62]. Additionally, KRAS and
BRAF mutations have been shown to be mutually exclusive,
with none of the KRAS-mutated samples carrying concomi-
tant BRAF mutations, or vice versa. This evidence had been
previously displayed in other studies [62–64].
Another retrospective study evaluated the effect of KRAS
downstream mutations on the efficacy of cetuximab in 1022
patients with chemotherapy-refractory mCRC treated with
cetuximab plus chemotherapy. Regarding the BRAF status,
BRAF mutants had a significantly lower RR (8.3% [2/24]
versus 38.0 [124/326] for wild types; OR, 0.15; 95% CI, 0.02–
0.51; 𝑝 = 0.0012) and disease-control rate (37.5% [9/24]
versus 77.3% [252/326]; OR, 0.176; 0.071–0.41; 𝑝 < 0.0001)
and shorter PFS (median, 8 versus 26 weeks in wild types;
HR, 3.74; 95% CI, 2.44–5.75; 𝑝 < 0.0001) and OS (median,
26 versus 54 weeks in wild types, HR, 3.03; 1.98–4.63; 𝑝 <
0.0001), when compared to wild types [65]. Although some
retrospective studies showed a decreased response to cet-
uximab/panitumumab in patients with BRAF mutations,
some patients may have some benefit from therapy with cet-
uximab as a front-line therapy [54, 66].
Therefore, the role of BRAF mutation in predicting
response to EGFR-targeting agents is still unclear. On the
other hand, its utility as a prognostic factor is more consen-
sual [54, 67]. Van Cutsem et al. showed that BRAF V600E
mutation was linked to a worse prognosis in KRAS wild-type
patients, regardless of which treatment they were submitted
to (cetuximab plus FOLFIRI versus FOLFIRI alone) [54].
Additionally, the above-mentioned COIN trial revealed that,
irrespective of treatment received, OS was shorter in patients
whose tumors had mutations in BRAF (𝑛 = 102, 8.8 months,
IQR: 4.5–16.1) than in those with BRAF wild-type tumors.
This data confirms once again that BRAF mutation is an
indicator of poor prognosis [57].
Despite the still controversial role of this downstream
mutation as a predictive marker, the NCCN panel recom-
mends the BRAF genotyping for stage IV CRC, at the time of
diagnosis. They consider the response to cetuximab/panitu-
mumab in BRAF mutant mCRC to be highly unlikely [6].
PTEN is a member of the EGFR signaling pathway, PI3K-
PTEN-AKT. In 2007, Frattini et al. showed that loss of PTEN
expression was predictive of cetuximab resistance in mCRC
patients. In a study involving 27 patients, 11 presented loss
of PTEN activity, and none of those responded to therapy
with cetuximab (𝑝 < 0.001). Furthermore, patients who
responded to cetuximab presented with PTEN expression
and wild-type KRAS genotype [68].
PIK3CA mutations were also linked with resistance to
EGFR-targeted therapy [69, 70]. However, the role of PIEK/
PTEN on predicting response to cetuximab/panitumumab
is still controversial. A recent study showed that neither
PIK3CA mutations nor PTEN expression levels would pre-
dict mCRC patients’ response to cetuximab [71].
Besides the molecules that integrate the EGFR signaling
pathways, molecules that act in an autocrine or paracrine
way may play a role in predicting the response to cetuximab/
panitumumab [72]. Amphiregulin and epiregulin are EGFR
ligands whose increased expression has been linked to a good
response to EGFR-targeted therapy [73, 74].
6. Bevacizumab
Bevacizumab is a monoclonal antibody that targets VEGF-
A and it is used in the treatment of mCRC in addition to
chemotherapy. 18 VEGF-A is a proangiogenic ligand which
(togetherwith other proangiogenicmolecules) has been asso-
ciated with tumor vascularization, progression, and metas-
tization. Moreover, it is known to blunt the cytotoxic effect
of chemotherapy by recruiting endothelial cells, protecting
the tumor from chemotherapy. Bevacizumab blocks this
process, by “normalizing” tumor’s vascularization and allow-
ing chemotherapy and oxygen to reach tumor cells [75].
Studies have been made in order to identify biomarkers
that could predict patients’ response to bevacizumab. High
VEGF-A levels have been associated with a poor clinical
outcome. However, they do not predict patients’ response to
bevacizumab, as shown by an initial comprehensive analysis
of plasma VEGF-A as a biomarker across multiple phase III
trials, which included the AVF2107 study [76]. In another
study, Hayashi et al. showed that an early increase in VEGF-A
circulating levels, after an initial decrease (in patients treated
with bevacizumab plus FOLFIRI), was associated with a
reduced PFS (𝑝 = 0.009) [77].
A 2013 study evaluated the predictive and prognostic
value of VEGF using samples from HORIZON II and III
trials, in which CRC patients were treated with cediranib,
a VEGF receptor (VEGFR) tyrosine kinase inhibitor. The
resulting data was consistent with previous studies, with high
levels of VEGF associated with worse prognosis, independent
of treatment received (HORIZON II OS: HR, 1.35; 95% CI,
1.12–1.63; HORIZON III OS: HR, 1.32; 95% CI, 1.12–1.54).
However, baseline VEGF was not predictive of response to
cediranib [78].
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Although several studies linked high VEGF levels to a
poor clinical outcome, most failed to demonstrate its value
as a predictive biomarker for chemotherapy response. Given
the importance of finding markers that would help select
candidates for treatment with bevacizumab, Bruhn et al.
conducted a trial, in which they determined tumor expres-
sion levels of the proangiogenic proteins (IL-6, IL-8, b-FGF,
PDGF-BB, andVEGF-A) inmCRCpatients. Individuals were
divided into two groups (high or low), according to their
levels of protein expression. Final data showed that low
VEGF-A levels were linked to a better RR for bevacizumab
(RR [low] 53% versus [high] 19%, interaction𝑝 = 0.03), while
“high” VEGF-A was prognostic for shorter PFS (unadjusted
HR: 1.34, 𝑝 = 0.06; adjusted HR: 1.55, 𝑝 = 0.008). The other
proangiogenic molecules showed neither a prognostic nor a
predictive value [79].
More recently, Tsai et al. performed a clinical trial to com-
pare pre- and posttherapeutic VEGF immunohistochemical
(IHC) expression in 57 mCRC patients treated with FOLFIRI
plus bevacizumab. Results showed that low posttherapeutic
VEGF expression (𝑝 < 0.001) and decreased peritherapeutic
VEGF expression (𝑝 < 0.001) were significantly predic-
tive factors for therapy response. Moreover, patients with
decreased peritherapeutic VEGF expression had improved 6-
month PFS than those with no peritherapeutic VEGF alter-
ations (𝑝 = 0.033) [80]. Given the inconsistent data regard-
ing the role of VEGF in response to therapy, its use as a
predictive biomarker for treatment with bevacizumab is cur-
rently not advised. Besides VEGF-A, several other molecules
play a role in angiogenesis, some of which have been the
object of clinical studies in order to identify biomarkers of
bevacizumab resistance. Although some of them have shown
a promising role as predictivemarkers, there is yet not enough
data to support their use in the clinical practice [77, 81–
83]. Further investigation is needed in the setting of mCRC
patients’ sensitivity/resistance to therapy with bevacizumab.
7. Microsatellite Instability
Microsatellites are short tandem DNA repeats that occur
throughout the genome. When mutations in microsatellites
occur in MMR genes (MSH2, MLH1, MSH6, and PMS2),
allowing DNA replication errors to occur, they give rise to a
defectiveMMR (dMMR) system.This is usually measured by
either the presence ofMSI or the absence of the protein prod-
ucts for theMMRgenes.MSI tumors can be classified asMSI-
H orMSI-low (MSI-L), depending on the extent of instability
in the marker tested. Tumors that do not present MSI are
calledmicrosatellite-stable (MSS).MSI-H occur in about 15%
of CRC (in this case, the hypermethylation of the MLH1 gene
promoter inactivates the mismatch repair), particularly in
stage II CRC. MSI-H are characterized by a proximal colon
predominance, older age, and female sex [84, 85].
MSI tumors have been linked to a good prognosis and
resistance to fluoropyrimidine-based chemotherapy alone. In
2003, Ribic et al. investigated the usefulness of MSI status
as a predictor of the benefit of adjuvant chemotherapy with
fluorouracil in stage II and stage III colon cancer. 570 patients
fromfive previous randomized trials who had been randomly
assigned to receive adjuvant 5-FU based chemotherapy after
surgical resection or no treatment were studied. Results
showed that 5-FU based therapy benefited those with MSS
or MSI-L tumors but not those who presented a MIS-H
phenotype. Patients with MSS who had MSI-L tumors and
were submitted to adjuvant therapy showed improved OS
(HR, 0.72; 95% CI, 0.53–0.99; 𝑝 = 0.04). By contrast, MSI-H
tumor patients did not benefit from adjuvant chemotherapy.
Patients who did not receive adjuvant therapy and presented
MSI-H tumors showed a better five-year rate of OS than
patients with tumors exhibiting a MSS or MSI-L status (HR,
0.31; 95% CI, 0.14–0.72; 𝑝 = 0.004) [86].
In a similar study, Sargent et al. examined the MMR
status as a predictor of adjuvant 5-FU based therapy benefit in
patients with stages II and III colon cancer. As in the previous
study, a group of 457 patients were randomly assigned to
receive either 5-FU based adjuvant therapy or no postsurgical
treatment. Patients with MSS tumors who received adjuvant
therapy showed a significantly improvement in DFS (HR,
0.67; 95% CI, 0.48–0.93; 𝑝 = 0.02). On the other hand,
defective MMR (dMMR) tumor patients showed no benefit
from 5-FU based therapy when compared with those treated
with surgery alone (HR, 1.10; 95% CI, 0.42–2.91; 𝑝 = 0.85). In
patients with stage II, dMMR CRC, treatment was associated
with reducedOS (HR, 2.95; 95%CI, 1.02–8.54; 𝑝 = 0.04) [87].
As mentioned above, MSI tumors are associated with
a good prognosis. Data from the PETACC-3 study showed
that the MSI-H profile occurs more often in stage II CRC
than in stage III (22% versus 12%, resp.; 𝑝 < 0.0001) [88].
Furthermore, evidence showed that these tumors may have a
decreased likelihood tometastasize. Koopman et al. collected
data from a phase III study in 820 advanced CRC patients, in
which dMMR was only found in 18 (3.5%) patients [85].
All these evidences suggest that stage II CRC with a MSI-
H profile may have good prognosis and would not benefit
from adjuvant 5-FU based chemotherapy. On the other hand,
in stage III disease, the benefit of adjuvant 5-FU based
chemotherapy is well documented. Flejou et al. studied the
benefit from adding oxaliplatin to a 5-FU based regimen in
stage III CRC, using data fromMOSAIC study patients.
This report had previously shown that combining oxali-
platin with 5-FU and LV improves OS andDFS, asmentioned
before [7]. After analyzing the MMR status of 986 patients,
Flejou and his colleagues displayed data that supports the
use of FOLFOX-4 regimen in stage III CRC with a MSI-H
profile. HR for stage III dMMR CRC are 0.56 (0.19–1.61) for
RFS, 0.51 (0.18–1.41) for DFS, and 0.44 (0.15–1.34) for OS,
respectively. HR for stage II dMMR tumors are 0.64 (0.11–
3.70) for RFS, 0.60 (0.17–2.09) for DFS, and 0.52 (0.13–2.10)
for OS, respectively [89].
While stage III CRC should be treated with 5-FU plus
oxaliplatin, stage II CRC treatment is more controversial, as
these patients do not benefit as much from adjuvant ther-
apy [62]. Patients with stage II disease often display good
prognosis and have been shown to be resistant to 5-FU
based regimens. Therefore, the NCCN currently recom-
mends determining MSI status for all patients with stage II
CRC, and adjuvant treatment should not be given to patients
with low-risk MSI-H tumors [6].
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Table 1: Summary of potential predictive biomarkers, available data, and current recommendations.
Drug Potential biomarkers Data available Current recommendations
5-FU
TS expression Inconsistent results None
TP expression
Inconsistent results; high

















Oxaliplatin ERCC1 Inconsistent results None
Cetuximab/panitumumab
KRAS mutation Resistance tocetuximab/panitumumab
Patient screening for
exon-2 KRAS mutations
BRAF V600E Inconsistent results; poorprognosis
BRAF genotyping for stage
IV CRC
PTEN loss Not predictive None
PIK3CA mutation Not predictive None






status for all stage II CRC
patients
5-FU: 5-fluorouracil; TS: thymidylate synthase; TP: thymidine phosphorylase; DPD: dihydropyrimidine dehydrogenase; UGT1A1: uridine diphosphate
glucuronosyltransferase 1A1; ERCC1: excision repair cross-complementation group 1; VEGF: vascular endothelial growth factor; MSI-H: microsatellite
instability-high.
Despite all these studies and NCCN recommendations, a
recent meta-analysis concluded that there are no differences
in the effect of 5-FU based chemotherapy, regarding the MSI
status.
Although there was improvement in DFS (HR, 0.62; 95%
CI, 0.54–0.71) and OS (HR, 0.65; 95% CI, 0.54–0.79) in
patients with MSS tumors treated with 5-FU compared with
those who were untreated and no improvement in the MSI
group (DFS [HR, 0.84; 95% CI, 0.53–1.32] and OS [HR, 0.66;
95% CI, 0.43–1.03]), the effect of adjuvant therapy was not
different at a statistical significant level [90].
Summary of potential predictive biomarkers, available
data, and current recommendations can be observed in
Table 1.
8. Discussion
CRC is one of the most frequent and deadliest cancers
worldwide [1]. Systemic chemotherapy in the adjuvant and
advanced setting has evolved greatly in the last decades
from basic cytotoxic agents to combination regimens and,
more recently, the advent of biological agents [5]. However,
patients often present different responses and grades of
toxicity to each regimen.Therefore, it is important to identify
biomarkers that could predict response to treatment, thus
helping us in selecting the best candidates for each drug. In
this paper, we reviewed themainmolecularmarkers that have
been studied in the setting of CRC.
Studies regarding EGFR-targeting agents cetuximab and
panitumumab have so far presented the most consistent
results. As discussed before, current guidelines recommend
screening patients for KRAS exon-2 mutations who are con-
sidered for cetuximab/panitumumab treatment. Wild-type
KRAS patients benefit from improvement in PFS, OS, and RR
with cetuximab, as shown in CRYSTAL and OPUS trials [17,
56]. In contrast, individuals who presented KRAS mutation
had shorter PFS and OS. However, COIN and NORDIC-VII
failed to show association between KRAS status and response
to therapy with cetuximab [57, 58].
In the PRIME trial, evidence showed that wild-type
individuals who received panitumumab displayed better PFS,
while those with mutant KRAS had no profit from this agent
[61].
Therefore, we hypothesized that, in those cases in which
KRAS wild-type patients appeared to be resistant to EGFR-
targeting agents, other unidentifiedmutationsmay be present
and may be the cause for the lack of response. Thus, further
studies should be addressed in order to investigate the role of
KRAS exon-3 and exon-4mutations as predictive biomarkers
for therapy with cetuximab/panitumumab.
BRAFV600Emutation has shown some prognostic value
in CRC patients. Nevertheless, its predictive value is still not
established, as current studies show inconsistent results. Still,
the NCCN recommends the screening for BRAF mutations
before initiating treatment with cetuximab/panitumumab
[6].
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Even though current data strongly supports the use of
chemotherapeutic agents in stage III and stage IV CRC, the
use of adjuvant treatment in stage II disease is still con-
troversial. In this setting, MSI status has been studied as a
predictor of the benefit of adjuvant chemotherapy. Tumors
displaying MSI-H phenotype have been shown to have better
prognosis, as demonstrated in the PETACC-3 study [88].
They also appear to have a lower likelihood to metastasize.
Moreover, scientific evidence established a predictive role for
theMSI status. In fact,MSI-H tumors seem to have no benefit
from 5-FU based chemotherapy [86, 87]. On the other hand,
in stage III CRC patients who were submitted to adjuvant
chemotherapy, MSI-H tumors have shown improvement in
DFS andOS [89]. So it seems that low-risk stage II CRC, as are
the ones that present MSI-H status, should not be submitted
to cytotoxic therapy. Conversely, high-risk stage II CRC may
have a clinical behavior closer to that of stage III disease
and sowould benefit from adjuvant chemotherapy.Therefore,
the determination of the MSI status in stage II CRC patients
is recommended to assess whether they are candidates to
receive adjuvant treatment.
Irinotecan has been linked to severe toxicity, particularly
in patients with a UGT1A1 deficiency.
The UGT1A1∗28 polymorphism seems to be responsible
for low UGT1A1 expression levels and thus a higher fre-
quency and severity of side effects. Moreover, in the Asian
population, the UGT1A1∗6 variant was also identified and
was associated with severe neutropenia and diarrhea [37].
Hence, recommendations advise the screening of all patients
for the UGT1A1∗28 andUGT1A1∗6 (in Japan) variants before
initiating treatment with irinotecan [39]. Although these
polymorphisms can help predict the occurrence of severe
toxicity, they are not predictors of therapy response.
So far, none of the othermarkers have proven a predictive
value to therapy response. Studies concerning ERCC1 have
shown contradictory results. Regarding the anti-VEGFR
agent bevacizumab, data revealed that high VEGF-A levels
are associated with poor prognosis.
However, studies addressing the role of VEGF as a
predictive biomarker have shown inconsistent results. Thus,
VEGF is not currently considered a usefulmarker of response
to bevacizumab. In the future, studies addressing the role
of other proangiogenic molecules should be conducted.
Several angiogenesis-related factors, such as IL-8, soluble
angiopoietin II (sANG-2), basic FGF (b-FGF), and stem
cell factor (SCF), have been shown to be increased in CRC
patients that did not respond to bevacizumab. However, the
available data is still insufficient [77].
9. Conclusion
In this paper, the authors reviewed the role of actual predic-
tive biomarkers in CRC. KRAS is the best studied marker
of response to cetuximab/panitumumab, with current use
in clinical practice. Similarly, patients’ genotyping for MMR
mutations is also recommended in stage II CRC. Regarding
toxicity, individuals who are candidates for therapy with
irinotecan should be tested for UGT1A1 polymorphisms.
Besides these, several other molecules have been studied
as potential biomarkers for chemotherapy sensitivity/resist-
ance. However, they are not used in practice, as they have not
yet proven their clinical value. Therefore, further investiga-
tion should be addressed in order to explore the potential role
of these promising markers.
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